Information Provided By: 
Fly News Breaks for January 13, 2017
DXCM
Jan 13, 2017 | 07:34 EDT
The Center for Medicare & Medicaid Services' announcement late last night that Dexcom's G5 continuous glucose monitoring system will now be covered and reimbursed is a "major win" for the company, JPMorgan analyst Michael Weinstein tells investors in a research note. The news comes just three weeks after the FDA's upgrade of Dexcom's label and is 12- 18 months ahead of Street expectations, the analyst adds. He believes Dexcom now has a "significant competitive advantage." Weinstein keeps an Overweight rating on the shares.
News For DXCM From the Last 2 Days
DXCM
Apr 26, 2024 | 09:14 EDT
DXCM
Apr 26, 2024 | 07:45 EDT
Canaccord analyst William Plovanic raised the firm's price target on DexCom to $145 from $144 and keeps a Buy rating on the shares. The firm said they reported a slight;ly better than expected Q1 as the company raised the low-end and mid-point of its revenue guidance and reiterated its adjusted GM/OM/EBITDA margins for 2024.
DXCM
Apr 25, 2024 | 17:21 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here
DXCM
Apr 25, 2024 | 16:05 EDT
DXCM
Apr 25, 2024 | 16:04 EDT
DXCM
Apr 25, 2024 | 15:11 EDT
Pre-earnings options volume in DexCom is 11.4x normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 5.8%, or $8.05, after results are released. Median move over the past eight quarters is 5.4%.
DXCM
Apr 25, 2024 | 13:09 EDT
